In addition to FGFR4, other kinases such as IRAK4, CKMT1B, PKN1, MAPKAPK3, Pim1, and STK4 in CRC, ALK in LC, CSNK1A1L and Her2/Neu in BC, and ECPKA in Non-Hodgkin’s lymphoma, breast, colon, and most highly incident cancers have been observed both as target of autoantibodies with diagnostic ability and as potential targets for therapy (30, 128, 190, 196, 197). Here, FGFR4 is linked to breast cancer.